Report Highlights Tomorrow's Drug-Delivery Coating Platforms

A new report spotlighting advances in coating technologies will help developers and users alike to analyze a range of different platforms, therapeutic targets, and market drivers. Offered by Greystone Research Associates (Amherst, NH), "Drug Coatings and Coated Device Drug Delivery: Evolving Technology, Emerging Opportunities" provides readers with a detailed understanding of enabling technologies, candidate devices, market participants, and commercial prospects.

Strides in drug-delivery coating platforms have given rise to a new generation of coating formulations that can reliably deliver therapeutic substances from the surface of an implanted medical device. In currently approved products, these devices provide a primary function, with the drug contributing therapeutic benefit that improves patient outcomes.

Currently more than two dozen companies are pursuing specialty coatings capable of delivering therapeutic agents. These participants are exploring several new and innovative approaches that include novel substrate geometries designed for the dual purpose of device integrity and drug delivery. Development efforts include new classes of drugs and novel coating application technologies and strategies.

This trend is expected to continue as competitors attempt to broaden their portfolios of technology offerings to accommodate the application needs of specific and evolving therapeutic protocols. In this environment, strategic relationships among drug, device, and coating companies will continue to be an essential element of success.

Device manufacturers and developers and suppliers of coating platforms: What do you think of this report? Where do you think coating technologies are headed in the next few years? Add new comments below.